At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 124 enrolled
Drug / intervention
Rotigotinedrug
Likely dose
Rotigotine 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopathic Parkinson's Disease
In Brief
A Phase 3 clinical trial evaluating Rotigotine for Parkinson's Disease. Completed, enrolled 124 participants.
Detailed Summary
This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
Primary CompletionDec 2007
First PostedJan 2008
TodayJul 2026
First PostedJan 15, 2008
Enrollment StartJul 1, 2007
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.5 years ago
Interventions
Rotigotinedrug
Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application